|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | February 19, 2008 | ||||
| Last Updated Date | November 16, 2009 | ||||
| Start Date ICMJE | February 2008 | ||||
| Estimated Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Participant Gain in Lean Body Mass [ Time Frame: Baseline, 15 days, and 29 days ] [ Designated as safety issue: No ] | ||||
| Original Primary Outcome Measures ICMJE |
To learn if the experimental study treatment (resistance training, aerobic exercise, and the use of atenolol, ibuprofen, melatonin, and Juven) can help to increase lean body mass (everything except fat) in cancer patients who experience cachexia. [ Time Frame: 1 Year ] [ Designated as safety issue: No ] | ||||
| Change History | Complete list of historical versions of study NCT00625742 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | |||||
| Original Secondary Outcome Measures ICMJE | |||||
| Descriptive Information | |||||
| Brief Title ICMJE | Multimodal Treatment Strategy for Cancer Cachexia | ||||
| Official Title ICMJE | An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia | ||||
| Brief Summary | The primary aim of this proposal is to present a novel, multimodal treatment strategy for increasing lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and aerobic exercise, targeted nutrient supplementation and pharmacologic intervention (melatonin, ibuprofen, and beta-blockers). -Researchers postulate that this strategy, together with the simultaneous management of symptoms that decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary objectives of improving clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days). |
||||
| Detailed Description | THE STUDY DRUGS: ATENOLOL is designed to block the negative effects of adrenaline (a stress hormone) on the heart. IBUPROFEN is designed to reduce inflammation caused by cancer. MELATONIN is a hormone that helps reduce inflammation and poor food absorption caused by cancer. It may also enhance the effects of ibuprofen. JUVEN is a nutritional supplement that is designed to help build muscle and slow muscle breakdown. SCREENING TESTS: Before you can start treatment on this study, you will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests will be performed:
STUDY DRUG ADMINISTRATION: You will take one (1) 20 mg capsule of melatonin every night. It can be taken with or without food. It should be taken with 8 ounces (1 cup) of water. You will take 400 mg of ibuprofen 3 times a day. Ibuprofen can be taken with food. It should be taken with 8 ounces of water. You may be asked to take 25 mg of atenolol, daily, by mouth, if your resting heart rate is greater than 110 beats per minute or your resting energy expenditure is 110% of what is expected for you. Atenolol can be taken with food. It should be taken with 8 ounces of water. At first, the dose of atenolol will be 25 mg, but it may be adjusted until your resting heart rate reaches a certain level. If you experience fatigue or depression that may be related to the use of atenolol, a lower and more tolerable dose will be used. The medication will be discontinued if symptoms remain. If you have a history of uncontrolled bronchial asthma or chronic obstructive pulmonary disease (COPD), you will not use atenolol. If you have mild to moderate controlled COPD, you will stop taking atenolol if intolerable side effects occur. You will drink 90 calories of Juven, twice a day. Juven is a powder supplement that is mixed into 8 ounces of water. It is available in orange or grape flavors. You will also be instructed to increase your daily calorie intake by at least 1,000 calories. To assist you in doing so, dietary advice will be given to you by a nurse or dietician. EXERCISE TRAINING: You will have 2 exercise training sessions a week. The sessions will combine resistance and graded aerobic training. RESISTANCE TRAINING (with Thera-bands) is designed to increase the muscle-building effects of a hormone called testosterone. Thera-bands are rubber bands that you can hold or put around your feet to provide resistance to your muscles when you bend and flex your arms and legs. You will be instructed in how to do 3 upper-body exercises (chest press, shoulder press, and arm pull down) and 3 lower-body exercises (leg press, leg extension, and leg flexion). At your first visit, a therapist experienced in physical rehabilitation and exercise medicine will make sure that all exercises are done correctly. Each repetition will take 12 seconds to complete (6 seconds to bend, then 6 seconds to straighten your arm or leg). When 6 repetitions are completed, the next week's set will be increased by 1 repetition. GRADED AEROBIC EXERCISE is a walking/running program that may help you exercise longer. Graded aerobic exercise involves walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate. There will be a 3-minute warm-up and a 3-minute cool-down before and after this exercise. During your first visit, you will be shown how to monitor your heart rate and how to exercise at 70-80% of your maximum heart rate. You will add 1 minute to your aerobic exercise at the start of each week. You will receive your own customized aerobic and resistance exercise program based on your range of motion and risk for falls, which will be evaluated by the study staff. If you experience chest pain, have a temperature over 100.4 °F, have a platelet count of lower than a certain level, have fresh bruises, or shortness of breath at rest, you will be advised to stop exercising until these are relieved. EVALUATIONS: While on study, within 3 days of the days listed below, the following measurements will be monitored:
LENGTH OF STUDY: You will be on study for 29 days (1 cycle). This is an investigational study. Melatonin and Juven are commercially available nutritional supplements and are exempt from FDA approval. Ibuprofen and atenolol are FDA approved and commercially available. However, in patients with cancer and cachexia, the study treatment (resistance training, aerobic exercise, and the use of Juven, atenolol, ibuprofen, and melatonin) is considered experimental. At this time, it is only being used in research. Up to 40 patients will be enrolled on this study. All will be enrolled at M. D. Anderson. |
||||
| Study Phase | |||||
| Study Type ICMJE | Interventional | ||||
| Study Design ICMJE | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study | ||||
| Condition ICMJE |
|
||||
| Intervention ICMJE |
|
||||
| Study Arms / Comparison Groups | Experimental: Exercise Program + Pharmacologic Intervention (Atenolol + Ibuprofen + Melatonin) + Nutritional Supplementation (Juven) | ||||
| Publications * | |||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Recruiting | ||||
| Estimated Enrollment ICMJE | 40 | ||||
| Completion Date | |||||
| Estimated Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years to 65 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE |
|
||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT ID ICMJE | NCT00625742 | ||||
| Responsible Party | Egidio Del Fabbro, MD/Assistant Professor, U.T.M.D. Anderson Cancer Center | ||||
| Study ID Numbers ICMJE | 2006-0739 | ||||
| Study Sponsor ICMJE | M.D. Anderson Cancer Center | ||||
| Collaborators ICMJE | |||||
| Investigators ICMJE |
|
||||
| Information Provided By | M.D. Anderson Cancer Center | ||||
| Verification Date | November 2009 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||